Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Therapeutic areas › Immunology

Immunology (56 companies · 22 conditions)

Conditions

Systemic Lupus Erythematosus 14 Rheumatoid Arthritis 13 Systemic Sclerosis 12 Rare Chronic Urticaria 8 Idiopathic Inflammatory Myopathies 8 Rare Ulcerative Colitis 8 Crohn's Disease 6 Sjögren's Syndrome 6 Dermatomyositis 3 Rare Food Allergy 3 Graves' Disease 3 Hereditary Angioedema 3 Rare Psoriatic Arthritis 3 ANCA-Associated Vasculitis 2 Rare Graft-versus-Host Disease 2 Rare IgG4-Related Disease 2 Rare Axial Spondyloarthritis 1 Cow's Milk Allergy 1 Leukocyte Adhesion Deficiency-I 1 Rare Peanut Allergy 1 Primary Humoral Immunodeficiency 1 Rare Transplant Rejection 1 Rare

Companies

Ticker Company Therapeutic areas In Immunology Lead stage Mkt cap Programs
ABVX Abivax Immunology 2 Phase 3 $7.50B 2
ACET Adicet Bio ImmunologyNeurology+2 Rare 5 Phase 1 $28.6M 8
ADMA Adma Biologics ImmunologyInfectious Disease Rare 2 Approved $2.82B 4
AGMB Agomab Therapeutics ImmunologyRespiratory Rare 1 Phase 2 $376M 4
ALLO Allogene Therapeutics ImmunologyOncology Rare 3 Phase 2 $360M 10
ANAB AnaptysBio DermatologyGI/Hepatology+2 Rare 1 Approved $1.39B 9
RCUS Arcus Biosciences DermatologyImmunology+1 1 Phase 3 $2.63B 8
AUTL Autolus Therapeutics HematologyImmunology+3 Rare 1 Approved $341M 12
BCRX Biocryst Pharmaceuticals DermatologyImmunology+1 Rare 2 Approved $1.98B 4
CABA Cabaletta Bio DermatologyImmunology+2 Rare 5 Phase 2 $280M 8
RNAC Cartesian Therapeutics ImmunologyNeurology+1 Rare 2 Phase 3 $230M 4
CLDX Celldex Therapeutics DermatologyImmunology+1 5 Phase 3 $2.35B 9
IPSC Century Therapeutics ImmunologyMetabolic+1 Rare 6 Phase 1 $304M 9
CMMB Chemomab Therapeutics GI/HepatologyImmunology+1 Rare 2 Phase 2 $10.6M 4
CLYM Climb Bio HematologyImmunology+1 Rare 2 Phase 2 $604M 8
CUE Cue Biopharma ImmunologyOncology 2 Phase 2 $136M 6
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 4 NDA Submitted $728M 10
DBVT DBV Technologies Immunology 2 NDA Submitted $3.29B 2
ELDN Eledon Pharmaceuticals ImmunologyMetabolic+1 Rare 1 Phase 2 $212M 3
ENTA Enanta Pharmaceuticals DermatologyImmunology+1 1 Approved $320M 7
EVMN Evommune DermatologyImmunology+1 3 Phase 2 $241M 6
FATE Fate Therapeutics ImmunologyOncology+1 Rare 4 Phase 2 $224M 10
IMVT Immunovant ImmunologyNeurology Rare 3 Phase 3 $6.31B 5
INAB IN8bio ImmunologyOncology 1 Phase 1 $10.0M 4
INSM Insmed CardiovascularImmunology+3 Rare 1 Approved $25.1B 15
NTLA Intellia Therapeutics CardiovascularImmunology Rare 1 NDA Submitted $1.59B 3
IONS Ionis Pharmaceuticals CardiovascularHematology+5 Rare 1 Approved $6.55B 29
JBIO Jade Biosciences ImmunologyRenal Rare 2 Phase 2 $958M 4
KYMR Kymera Therapeutics DermatologyImmunology+1 Rare 1 Phase 2 $11.2B 5
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare 1 NDA Submitted $302M 7
LQDA Liquidia CardiovascularImmunology+1 Rare 1 Approved $3.97B 9
MGTX MeiraGTx ImmunologyMetabolic+2 Rare 1 Phase 3 $864M 16
MESO Mesoblast CardiovascularGI/Hepatology+2 Rare 0 Approved $1.85B 5
INKT MiNK Therapeutics ImmunologyOncology+1 Rare 1 Phase 2 $52.8M 8
GLUE Monte Rosa Therapeutics CardiovascularDermatology+3 Rare 1 Phase 2 $903M 7
MLTX MoonLake Immunotherapeutics DermatologyImmunology Rare 2 NDA Submitted $981M 4
NKTR Nektar Therapeutics DermatologyImmunology+2 1 Phase 3 $1.27B 11
NKTX Nkarta ImmunologyNeurology+1 Rare 5 Phase 1 $124M 8
NRIX Nurix Therapeutics ImmunologyNeurology+1 1 Phase 3 $1.67B 13
ORKA Oruka Therapeutics DermatologyImmunology Rare 1 Phase 2 $6.81B 7
PTN Palatin Technologies ImmunologyMetabolic+1 Rare 1 Phase 3 $11.2M 8
PALI Palisade Bio Immunology 2 Phase 2 $197M 3
PCSA Processa Pharmaceuticals GI/HepatologyImmunology+2 Rare 2 Phase 2 $5.4M 7
PTGX Protagonist Therapeutics DermatologyHematology+2 Rare 3 Approved $8.62B 12
QNRX Quoin Pharmaceuticals DermatologyImmunology Rare 1 Phase 2 $257M 4
RCKT Rocket Pharmaceuticals CardiovascularImmunology Rare 1 Approved $262M 4
SEPN Septerna ImmunologyMetabolic+1 Rare 3 Phase 1 $2.28B 5
SYRE Spyre Therapeutics DermatologyImmunology Rare 9 Phase 2 $9.86B 10
SNDX Syndax Pharmaceuticals ImmunologyOncology Rare 1 Approved $852M 7
TLSA Tiziana Life Sciences ImmunologyNeurology Rare 1 Phase 2 $87.8M 5
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 1 Approved $231M 27
VRDN Viridian Therapeutics ImmunologyOphthalmology 2 Approved $3.24B 7
VOR Vor Biopharma ImmunologyNeurology Rare 1 Phase 3 $1.22B 2
XNCR Xencor ImmunologyNeurology+1 Rare 10 Approved $2.68B 28
ZBIO Zenas BioPharma DermatologyImmunology+2 Rare 3 NDA Submitted $1.92B 11
ZURA Zura Bio DermatologyImmunology Rare 1 Phase 2 $394M 5